|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0017262,
umls-concept:C0078058,
umls-concept:C0185117,
umls-concept:C0205179,
umls-concept:C0242792,
umls-concept:C0449438,
umls-concept:C0597298,
umls-concept:C0677886,
umls-concept:C1256770,
umls-concept:C1306673,
umls-concept:C1512288,
umls-concept:C1706406,
umls-concept:C2603343,
umls-concept:C2911684
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-11-3
|
|
pubmed:abstractText |
The Gynecologic Oncology Group (GOG) examined the association between the relative expression of the DeltaNp63alpha isoform and clinicopathologic variables, p53 status, angiogenic markers, progression-free survival (PFS) and overall survival (OS) in epithelial ovarian cancer (EOC).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1095-6859
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
424-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:19767063-Aged,
pubmed-meshheading:19767063-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19767063-Disease-Free Survival,
pubmed-meshheading:19767063-Epithelial Cells,
pubmed-meshheading:19767063-Female,
pubmed-meshheading:19767063-Humans,
pubmed-meshheading:19767063-Middle Aged,
pubmed-meshheading:19767063-Neoplasm Staging,
pubmed-meshheading:19767063-Ovarian Neoplasms,
pubmed-meshheading:19767063-Protein Isoforms,
pubmed-meshheading:19767063-Randomized Controlled Trials as Topic,
pubmed-meshheading:19767063-Trans-Activators,
pubmed-meshheading:19767063-Transcription Factors,
pubmed-meshheading:19767063-Tumor Suppressor Proteins,
pubmed-meshheading:19767063-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
|
|
pubmed:affiliation |
Duke University Medical Center 3079, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA. jewelle@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
